Biogen | BIIB - Cash And Equivalent


Biogen reported $1.28B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sanofi EUR 5.54B 2.11B Mar/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026